Qiagen (NYSE:QGEN) Earns Neutral Rating from JPMorgan Chase & Co.

Qiagen (NYSE:QGEN)‘s stock had its “neutral” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a research report issued on Thursday, Benzinga reports. They currently have a $52.00 target price on the stock, down from their prior target price of $55.00. JPMorgan Chase & Co.’s target price points to a potential upside of 3.30% from the stock’s previous close.

A number of other equities research analysts have also recently weighed in on QGEN. UBS Group began coverage on Qiagen in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $47.00 price objective for the company. Berenberg Bank set a $45.50 price objective on Qiagen and gave the company a “hold” rating in a report on Tuesday, July 14th. Stifel Nicolaus set a $40.00 target price on shares of Qiagen in a research report on Friday, August 7th. Morgan Stanley reaffirmed an “overweight” rating on shares of Qiagen in a report on Friday, September 11th. Finally, Barclays set a $40.00 price target on shares of Qiagen and gave the company an “equal weight” rating in a research report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $44.43.

Qiagen Stock Performance

Shares of QGEN stock opened at $50.34 on Thursday. The stock’s 50-day moving average is $44.15 and its two-hundred day moving average is $40.51. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. Qiagen has a 1 year low of $32.53 and a 1 year high of $57.81. The firm has a market cap of $10.37 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 4.87 and a beta of 0.61.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.02. The business had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The business’s quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the business earned $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. Analysts predict that Qiagen will post 2.43 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in QGEN. Hilltop National Bank purchased a new position in Qiagen during the second quarter worth about $50,000. Integrated Wealth Concepts LLC acquired a new stake in Qiagen in the second quarter valued at about $59,000. Allworth Financial LP boosted its holdings in Qiagen by 20.8% in the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock valued at $72,000 after purchasing an additional 317 shares in the last quarter. denkapparat Operations GmbH purchased a new stake in Qiagen in the 2nd quarter valued at approximately $105,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in Qiagen by 46.8% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,746 shares of the company’s stock valued at $110,000 after purchasing an additional 876 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen News Summary

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: EQT takeover offer is the main catalyst. EQT has agreed to acquire Qiagen in an all-cash transaction valued at approximately $12.1 billion, offering €46.50 per share for all outstanding shares. The proposal confirms earlier reports that EQT was in advanced discussions and gives investors a potential cash-exit value. Qiagen to Be Acquired by EQT for $12.1 Billion in All-Cash Deal
• Positive Sentiment: Preliminary Q3 results were solid. Qiagen reported preliminary net sales of $548 million and adjusted diluted EPS of $0.65, both at reported and constant exchange rates. The results indicate continued operating resilience ahead of the company’s full Q3 report scheduled for November 4, 2026. QIAGEN reports preliminary Q3 2026 results
• Positive Sentiment: Robert W. Baird raised its target. Baird increased its Qiagen price target from $50 to $52 and maintained an “outperform” rating, signaling further potential upside if the transaction does not fully determine the share price. Baird raises Qiagen price target
• Neutral Sentiment: The takeover now shifts attention from fundamentals to deal completion. Investors will likely focus on shareholder, regulatory and other closing conditions, as well as whether the proposed consideration represents the final value available to shareholders.
• Negative Sentiment: Transaction risk remains. Until the EQT acquisition closes, Qiagen remains exposed to potential delays, revised terms or failure to complete the deal. The takeover also limits the near-term importance of older standalone valuation estimates, including the previously reported brokerage consensus target of $43.93.

About Qiagen

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.